Cancer Trial Using Monoclonal Antibody Finds Remission in Every Patient: Report

Contact Your Elected Officials
The Epoch Times Header

cancer trial has reportedly become the first in the world to completely remove the disease in every patient, according to a study published Sunday in the New England Journal of Medicine.

The study, titled “PD-1 Blockade in Mismatch Repair—Deficient, Locally Advanced Rectal Cancer” was conducted among 12 rectal cancer patients, all of which had a “clinical complete response,” according to the authors, led by Dr. Andrea Cercek of the Memorial Sloan Kettering Cancer Center, New York City.

Doctors have been unable to see any evidence of tumors among the patients when using magnetic resonance imaging, fludeoxyglucose F 18 injections, physical examinations, or via endoscopic evaluations, according to researchers.

Furthermore, the patients continued to show no signs of cancer during follow-ups ranging from 6 to 25 months and have not had to undergo surgery or receive radiation and chemotherapy.

“No adverse events of grade 3 or higher have been reported,” the authors noted.

Specifically, the rectal cancer patients were given dostarlimab, a monoclonal antibody, every 3 weeks for 6 months. The patients had mismatch repair-deficient stage two or three rectal adenocarcinomas, a type of cancer.

The median age of the patients enrolled was 54 years and 62 percent were women.

Typically, such cancer patients would have needed to undergo often debilitating treatments like chemotherapy, radiation, or surgery and in extreme cases, be fitted with colostomy bags.

However, after taking dostarlimab, which is sold under the brand name Jemperli, no cases of progression or recurrence were reported in the patients who underwent the study.

Dostarlimab is already approved by the U.S. Food and Drug Administration for use in the treatment of adult patients with mismatch repair-deficient recurrent or advanced solid tumors. Rectal cancer is an off-label use, according to Medscape.

According to Drugs.com, the cost of Jemperli intravenous solution (500 mg/10 mL) is around $11,201 for a supply of 10 milliliters.

The results of the study were also presented at the American Society of Clinical Oncology 2022 annual meeting.

By Katabella Roberts

Read Full Article on TheEpochTimes.com

The Epoch Times
The Epoch Timeshttps://www.theepochtimes.com/
Tired of biased news? The Epoch Times is truthful, factual news that other media outlets don't report. No spin. No agenda. Just honest journalism like it used to be.

Democrats are Losing by Pushing Their Dirty CR Bill

Talk is going around about the “Democrats Dirty CR” and the “Republicans Clean CR”.

NCAA streamlines transfer portal

The NCAA lords of the Division I Administrative Committee have unveiled a fresh batch of transfer portal reforms.

Section 230 Immunity, Defective Design and Trial Lawyers (Part 2)

Congress granted social media platforms Section 230 immunity even when children are harmed, trial lawyers found a way to bypass protection.

A Tale Of Two Political Parties

While the GOP, led by Trump, has produced results, Democrats offer horrible policies and candidates, presenting a vivid contrast to the American people. 

The Case for Western Islam

The suggestion of a expression of Islam which emerges from western culture is one that comes from a place of love.

Democrats are Losing by Pushing Their Dirty CR Bill

Talk is going around about the “Democrats Dirty CR” and the “Republicans Clean CR”.

Biden Undergoing Radiation, Hormone Treatment for Prostate Cancer

Former President Biden has begun receiving a combination of radiation and hormone treatments for prostate cancer, spokesperson announced.

Homan Says DOJ Probing Funding Behind ‘Organized’ Attacks on ICE

Border czar, Homan said DOJ launched an investigation into funding for what he called “organized” attacks on federal immigration enforcement agents.

There Are No Survivors in the Blast at a Tennessee Explosives Factory, Sheriff Says

The blast in rural Tennessee that leveled an explosives plant and was felt for miles around left no survivors, authorities said Saturday

Trump Names Longtime Adviser Dan Scavino to Key Personnel Position

One of President Trump’s longtime advisers, Dan Scavino, is going to be in charge of selecting and appointing key positions within the executive branch.

First Lady’s Effort Helped Reunite 8 War-Displaced Children With Their Families

First lady Melania Trump said 8 children impacted by the fighting between Ukraine and Russia were reunited with their families on Oct. 9.

Trump to Impose New 100 Percent Tariff on China on Nov. 1

President Trump said that the US will impose an additional 100 percent tariffs on Chinese goods and export controls on critical software starting on Nov. 1.

Trump Admin Agrees to $20 Billion Rescue Plan for Argentina

The U.S. government has finalized a $20 billion economic rescue plan for Argentina, Treasury Secretary Scott Bessent announced on Oct. 9.
spot_img

Related Articles

Popular Categories

MAGA Business Central